Sarepta to soon submit sNDAs for traditional approval for Duchenne treatments
Source: SeekingAlpha
2026-03-19 10:13:35 ET
More on Sarepta Therapeutics
- Sarepta Therapeutics, Inc. (SRPT) Presents at TD Cowen 46th Annual Health Care Conference Transcript
- Sarepta Therapeutics, Inc. 2025 Q4 - Results - Earnings Call Presentation
- Sarepta Therapeutics, Inc. (SRPT) Q4 2025 Earnings Call Transcript
- Sarepta Therapeutics begins search for CEO as Douglas Ingram announces retirement; shares down
- Sarepta outlines $1.2B–$1.4B 2026 revenue target as ELEVIDYS educational push ramps up
Read the full article on Seeking Alpha
For further details see:
Sarepta to soon submit sNDAs for traditional approval for Duchenne treatments
Sarepta Therapeutics Inc.
NASDAQ: SRPT
SRPT Trading
4.07% G/L:
$22.52 Last:
846,396 Volume:
$21.92 Open:
SRPT Latest News
March 25, 2026 08:05:00 am
Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
March 24, 2026 04:05:00 pm
Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
SRPT Stock Data
$1,921,797,010
96,823,361
N/A
132
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
